A Phase 2, Single-Blind, Randomized Study of Safety and Immunogenicity Following Vaccination With Single or Double Doses of HEPLISAV in Adults With End-Stage Renal Disease
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2017
At a glance
- Drugs V 270 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Dynavax Technologies
- 14 Apr 2010 Results presented in a poster session at the National Kidney Foundation Spring Clinical Meeting, as reported by Dynavax Technologies.
- 21 Apr 2008 Added Dynavax Technologies as a sponsor (from ClinicalTrials.gov).
- 21 Apr 2008 Status changed from suspended to discontinued. According to ClinicalTrials.gov, this study is on clinical hold.